Blood Test Study Using AI to Detect Cancer Early and Track Treatment
Tests an AI-based blood test in adults with several cancers, including breast and lung.
Key facts
- Who runs it
- Javier Toledo
- Where
- Lagos, NigeriaSee the siteAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
- Status
- Recruiting
- People taking part
- 6,000 people, planned
- Started
- 20 Dec 2025
- Expected to end
- 1 Aug 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- DiNanoQ: A multi-cancer early detection (MCED) blood test
- DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Record updated
- 2 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 75 with a confirmed diagnosis of one of several common cancers. Blood samples are used to develop an AI-based blood test.
- Age
- 40 to 75 years
- Sex
- Women and men can join.
- Disease stage
- Confirmed diagnosis of non-small cell lung cancer, glioblastoma, colorectal cancer, liver cancer (hepatocellular carcinoma), breast cancer, prostate cancer, ovarian cancer or pancreatic cancer. In the second phase: liver cancer or non-small cell lung cancer only.
- Earlier treatment
- Cannot have used anticoagulant or antiplatelet drugs within the past 2 weeks (first phase).
Main reasons for not taking part
- Currently pregnant (first phase)
- Any active infectious disease (first phase)
- Anticoagulant or antiplatelet drugs within the past 2 weeks (first phase)
- Another cancer, unless it has been in remission for at least 5 years (second phase)
- Medical or psychological conditions that make it hard to follow the study steps
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age: Adults aged 40 years or older
- Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer
- Adults aged 40 years or older
- Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)
- Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation)
Who cannot take part
- Use of anticoagulant or antiplatelet drugs within the past 2 weeks
- Presence of any active infectious diseases
- Any medical or psychological conditions that may affect the participant's ability to comply with study procedures; Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
- Presence of another malignancy unless it has been in remission for at least 5 years
- Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes
- Currently pregnant
Other criteria
- Phase 1 (Common Cancer Early Detection - CCANED)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Where in Nigeria
Also in 2 other countries, 3 sites
- NSIA- Lagos University Teaching Hospital Cancer CentreLagos, NigeriaContact: Adewumi Alabi, OncologyTaking people
About the trial
What the trial wants to find out
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
The 3 groups in the trial
- Cancer Patients (Phase 1)
This arm will include 3,500 individuals with confirmed diagnoses of common cancers such as Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, and Pancreatic Cancer.
Treatment: DiNanoQ: A multi-cancer early detection (MCED) blood test
- Healthy Individuals
This arm will consist of 1,500 age- and sex-matched cancer-free individuals serving as controls.
Treatment: DiNanoQ: A multi-cancer early detection (MCED) blood test
- Cancer Patients Undergoing Treatment
This cohort will include 1,000 patients diagnosed with Hepatocellular Carcinoma (HCC) or Non-Small Cell Lung Cancer (NSCLC) across stages I to IV who are about to commence standard cancer therapy.
Treatment: DiNanoQ: A multi-cancer early detection (MCED) blood test and DiNanoTrack: Therapeutic Response Monitoring Blood Test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
- Plain-language title
- Blood Test Study Using AI to Detect Cancer Early and Track TreatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06717295, who can take part
- Record updated
- 2 January 2026